Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...

Data analytics firm Verisk said on Wednesday it will buy AccuLynx, which makes software for roofing contractors, for $2.35 ...

Analysts say the departure of the CBER head may alleviate overhang in the cell and gene therapy space. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and ...

The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...

Fintel reports that on July 29, 2025, William Blair downgraded their outlook for NeoGenomics (NasdaqCM:NEO) from Outperform ...

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

Vertiv Holdings ( NYSE: VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...